Neurology

Top news of the day from across the health care landscape.

Top news of the day from across the healthcare landscape.

A recent study has suggested that starting patients on multiple sclerosis medication soon after they show initial signs of the disease could prolong the time before the condition becomes fully diagnosable.

Multiple sclerosis is an incurable immune-mediated inflammatory disease that produces symptomatic episodes months or years apart in different anatomic locations.

Test delivers the results of a multiple sclerosis diagnosis in as few as 7 days.

New MS diagnoses are steadily on the rise.

New Alexa skill helps spread MS education and awareness.

Fatigue and limitations in leg function may increase progress from relapsing-remitting MS to secondary progressive MS in older adults.

Individuals with MS are 3 to 6 times more likely to develop seizures.

The challenges of living a normal, active life while managing multiple sclerosis.

Genetics that determine physical traits may play a large role in prevalence of conditions such as multiple sclerosis, autism, and diabetes.

Diseases such as multiple sclerosis, lupus, and psoriasis showed a statistically significant association with dementia.

Investigational MS drug lowers the relapse rate during a phase 3 clinical trial.

Some patients who switch from treatment with Gilenya to Lemtrada experience disease progression.

Central nervous system lesions may impede cognitive and sensorimotor function in patients with MS.

A majority of patients with multiple sclerosis treated with chemotherapy and a stem cell transplant remained in remission for at least 5 years.

One round of investigational combination treatment may be more effective than long-term treatment for multiple sclerosis.

Patients with MS administered ozanimod experienced less relapses over 1 year.

A new therapeutic agent prevented neuronal damage and preserved function in an MS mouse model.

Liver injury reported in patients with oral multiple sclerosis drug.

The Cleveland Clinic received multi-million dollar awards to further multiple sclerosis and bone marrow failure syndrome research.

Current stage 3 trials for multiple sclerosis medications may address several unmet needs in the patient population.

Roughly half of MS patients had hyposmia at the beginning of the study.

95% of survey respondents support medical marijuana treatment for multiple sclerosis.

A change from fingolimod to alemtuzumab caused significant disease activity in patients with MS.